KAPA earnings analysis
What we found in KAPA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q excerpt contains no income statement, balance sheet, cash flow, segment, or quantitative outlook data, so revenue, margins, EPS, free cash flow, and period-over-period trends cannot be assessed. The principal disclosed developments are the July 16, 2026 Bayer research agreement and continued ineffective disclosure controls as of June 30, 2026. The filing also highlights a potentially more severe NYSE American delisting risk involving immediate suspension or delisting mechanisms with limited or no cure periods.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Bayer research agreement included
- The filing includes Exhibit 10.2, an Agreement for the Support of Investigator/Institution Initiated Research with Bayer HealthCare Pharmaceuticals Inc., dated July 16, 2026.
- No unregistered equity sales
- The company reported no unregistered sales of equity securities during the quarter ended June 30, 2026.
- No new control changes reported
- Management stated that there were no changes during the period ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Disclosure controls remain ineffective
- The CEO and CFO concluded that disclosure controls and procedures were not effective at a reasonable assurance level as of June 30, 2026. The previously disclosed material weakness also continued, including insufficient review procedures, segregation of duties, and process documentation.
- NYSE American delisting risk
- The filing adds a specific NYSE American listing risk under Item 1A, warning that potential rule changes could permit immediate trading suspensions and delisting proceedings with limited or no compliance or cure periods. Delisting could impair liquidity, trading price, investor confidence, and access to capital markets.
- Control remediation remains incomplete
- The company states that material weaknesses and control deficiencies will not be fully remediated until controls have operated effectively for a sufficient period of time, indicating that remediation remains incomplete as of June 30, 2026.
What they said about what is next.
The provided 10-Q text contains no quantitative revenue, EPS, margin, cash flow, or other forward financial guidance. The filing does not state that prior guidance was raised, maintained, lowered, or withdrawn.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Kairos Pharma's Q1 2026 filing shows continued operational losses with no revenue generated during the quarter. Net loss increased to $1.654 million from $1.262 million in Q1 2025, indicating growing operational…
- 10-K · March 31, 2026
- Kairos Pharma (KAPA) is a clinical-stage oncology company with a seven-drug pipeline (five Kairos-developed candidates plus ENV 105 and ENV 205 from its Enviro acquisition) focused on overcoming immune suppression and…
- 10-Q · November 14, 2025
- Kairos Pharma reported no revenue and a quarterly net loss of $1,398 thousand (loss per share $(0.07)) for the three months ended September 30, 2025. Cash increased to $5,575 thousand following net financing proceeds of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KAPA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever